{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field a243e829-7bf5-401c-ab51-a9460103d0db --><h2>What  investigations are advised in a woman with suspected pelvic inflammatory disease?</h2><!-- end field a243e829-7bf5-401c-ab51-a9460103d0db -->","summary":"","htmlStringContent":"<!-- begin item 6e6d3c7f-c337-4bda-b9e3-a9460103caab --><!-- begin field 0ed11255-a5c0-4120-9367-a9460103d106 --><p><strong>A diagnosis of pelvic inflammatory disease (PID) should be made on clinical grounds. Do not delay making a diagnosis and initiating treatment whilst waiting for the results of laboratory tests. Negative swab results do not rule out a diagnosis of PID.</strong></p><p><strong>Consider referring the woman to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service to facilitate screening for infections and for contact tracing. </strong></p><ul><li><strong>Offer a pregnancy test </strong>to all sexually active women who are potentially fertile, to exclude ectopic pregnancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/ectopic-pregnancy/\">Ectopic pregnancy</a>.</li><li><strong>Consider taking a high vaginal swab</strong> to exclude other vaginal infections, such as bacterial vaginosis and candidiasis.<strong> </strong>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">Bacterial vaginosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">Candida - female genital</a>. </li><li><strong>Test for the following:</strong><ul><li>Chlamydia. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/diagnosis/testing-to-confirm-the-diagnosis/\">Testing to confirm the diagnosis</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a> for more information.</li><li>Gonorrhoea. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/diagnosis/confirmation-of-diagnosis/\">Confirmation of diagnosis</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a> for more information.</li><li><em>Mycoplasma genitalium. </em>Local availability of <em>M. genitalium</em> testing currently varies but implementation of testing is strongly recommended to guide the choice of appropriate treatment.</li></ul></li><li><strong>If possible, look for endocervical or vaginal pus cells under a microscope on a wet-mount vaginal smear.</strong><ul><li>If absent, a diagnosis of PID is unlikely.</li><li>Excess leucocytes are associated with PID, but they are also found in women with lower genital tract infection.</li></ul></li><li><strong>Consider performing the following tests (which if elevated support the diagnosis of PID but are non-specific):</strong><ul><li>Erythrocyte sedimentation rate (ESR).</li><li>C-reactive protein.</li><li>Leucocyte count.</li></ul></li><li><strong>Offer blood tests for the following:</strong><ul><li>HIV. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/diagnosis/symptomatic-hiv-infection/#how-to-test-for-hiv\">How to test for HIV</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a>.</li><li>Syphilis. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/management/management-of-suspected-syphilis/\">Management of suspected syphilis</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a> for more information.</li></ul></li><li><strong>Offer chlamydia screening </strong>to all sexually active people younger than 25 years of age, annually, or more frequently if they have changed their partner. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a> for more information.</li><li><strong>Consider other investigations, as appropriate.</strong><ul><li>Ultrasound scanning is of limited value for uncomplicated PID but is helpful if an abscess or hydrosalpinx is suspected. Doppler ultrasound can detect increased blood flow associated with pelvic infection and may be useful, but it cannot differentiate between PID and other causes of increased vascularity, such as endometriosis.</li><li>MRI (magnetic resonance imaging) or CT (computed tomography) scanning of the pelvis may be helpful in differentiating PID from <a class=\"topic-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/diagnosis/differential-diagnosis/\">alternative diagnoses</a>, but they are not indicated routinely. </li></ul></li></ul><!-- end field 0ed11255-a5c0-4120-9367-a9460103d106 --><!-- end item 6e6d3c7f-c337-4bda-b9e3-a9460103caab -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"1ee8a7f8-dc20-5d71-b837-21c79e136cf3","slug":"basis-for-recommendation-ad1","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 20cbb918-ef52-49db-908f-a94601768dad --><h3>Basis for recommendation</h3><!-- end field 20cbb918-ef52-49db-908f-a94601768dad -->","summary":null,"htmlStringContent":"<!-- begin item ad1389e8-35a8-4a56-af63-a94601768cbe --><!-- begin field 4accdf44-3ee0-4e32-939a-a94601768db2 --><p>These recommendations are based largely on the British Association for Sexual Health and HIV (BASHH) guideline <em>2018 United Kingdom national guideline for the management of pelvic inflammatory disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>] and the <em>European guideline for the management of pelvic inflammatory disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Ross, 2017</a>].</p><h4>Diagnosing pelvic inflammatory disease (PID)</h4><ul><li>Expert opinion in the BASHH guideline is that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>]:<ul><li>A diagnosis of pelvic inflammatory disease (PID) should be considered (and usually empirical antibiotic treatment offered) in any sexually active woman who has recent onset lower abdominal pain associated with local tenderness on bimanual vaginal examination, in whom pregnancy has been excluded and no other cause for the pain has been identified.</li><li>The diagnosis of PID based only on positive examination findings, in the absence of lower abdominal pain, should only be made with caution.</li></ul></li></ul><h4>Testing for gonorrhoea, chlamydia, and <em>Mycoplasma genitalium</em></h4><ul><li>Testing for gonorrhoea, chlamydia, and <em>M. genitalium </em>in the lower genital tract is recommended because a positive result supports the diagnosis of PID and may alter subsequent treatment, although a negative result does not exclude PID [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>]. </li></ul><h4>Interpreting the results of a wet-mount smear</h4><ul><li>The absence of endocervical or vaginal pus cells suggests that the diagnosis is <em>not </em>PID, but their presence is non-specific [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Ross, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>].<ul><li>The negative predictive value for a diagnosis of PID is high (among those who had a negative test result, the probability of being disease-free is 95%).</li><li>The positive predictive value is low (among those who have a positive test result, the probability of disease is only 17%).</li></ul></li></ul><h4>Erythrocyte sedimentation rate (ESR), C-reactive protein, and leucocyte count</h4><ul><li>An elevated ESR, C-reactive protein, and leucocyte count supports the diagnosis of PID but is non-specific. Levels are usually only abnormal in moderate or severe PID [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Ross, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>].</li></ul><h4>Offering blood tests for HIV and syphilis </h4><ul><li>This recommendation is based on the Public Health England (PHE) guideline <em>Management and laboratory diagnosis of Abnormal Vaginal Discharge: Quick Reference Guide for Primary Care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">PHE, 2013</a>], the BASHH <em>UK national guideline for the management of gonorrhoea in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2011</a>], and the BASHH <em>UK national guideline for the management of infection with Chlamydia trachomatis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2015</a>], which recommend offering blood tests for HIV and syphilis<strong> </strong>if testing for gonorrhoea and chlamydia.</li></ul><h4>Offering an annual chlamydia screen to women younger than 25 years</h4><ul><li>This recommendation is based on expert opinion in the PHE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">PHE, 2013</a>] and the BASHH guideline on the management of chlamydia<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2015</a>].</li></ul><!-- end field 4accdf44-3ee0-4e32-939a-a94601768db2 --><!-- end item ad1389e8-35a8-4a56-af63-a94601768cbe -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}